Exporter

EN
FR
Vincristine
Statut de médicament essentiel
Description générale

INN
Vincristine
Codes ATC
L01CA02
Type de médicament
Chemical agent
Historique des statuts LME
Ajouté en 2015 (TRS 994) pour Retinoblastoma
Ajouté en 2015 (TRS 994) pour Follicular lymphoma
Ajouté en 2015 (TRS 994) pour Hodgkin lymphoma
Wikipédia
Vincristine
DrugBank
Vincristine
Recommandations
Section
Cytotoxic medicines
  • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
  • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Indications
Rhabdomyosarcoma primary site Diffuse large B-cell lymphomas Malignant trophoblastic neoplasms of placenta Hodgkin lymphoma Kaposi sarcoma of unspecified primary site Follicular lymphoma Retinoblastoma Ewing sarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Langerhans cell histiocytosis